Reshape Lifesciences Inc (RSLS)

Jun 3, 2025, 8:31 AM EDT - 4 days ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

May 21, 2025, 8:31 AM EDT - 17 days ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:32 AM EDT - 26 days ago

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ORLA

May 7, 2025, 8:31 AM EDT - 4 weeks ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

May 2, 2025, 8:31 AM EDT - 5 weeks ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

Apr 28, 2025, 8:31 AM EDT - 5 weeks ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Apr 21, 2025, 8:31 AM EDT - 6 weeks ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Apr 10, 2025, 5:54 PM EDT - 2 months ago

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

Apr 9, 2025, 4:05 PM EDT - 2 months ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

Apr 7, 2025, 4:05 PM EDT - 2 months ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Mar 21, 2025, 11:35 AM EDT - 2 months ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Mar 10, 2025, 8:31 AM EDT - 3 months ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Feb 25, 2025, 8:31 AM EST - 3 months ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Feb 15, 2025, 11:17 PM EST - 3 months ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Feb 3, 2025, 8:31 AM EST - 4 months ago

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Jan 13, 2025, 8:31 AM EST - 5 months ago

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Nov 14, 2024, 7:43 PM EST - 7 months ago

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 7 months ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Nov 12, 2024, 8:31 AM EST - 7 months ago

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

Nov 11, 2024, 8:31 AM EST - 7 months ago

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

Sep 19, 2024, 8:31 AM EDT - 9 months ago

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

Aug 15, 2024, 8:42 PM EDT - 10 months ago

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 8:31 AM EDT - 10 months ago

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 19, 2024, 8:05 AM EDT - 11 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

CHUY

Jul 9, 2024, 12:13 PM EDT - 11 months ago

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

Jul 9, 2024, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

May 17, 2024, 8:57 PM EDT - 1 year ago

ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

May 14, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 1, 2024, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

Mar 4, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

Feb 22, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

Jan 24, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

Dec 20, 2023, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

Dec 12, 2023, 4:05 PM EST - 1 year ago

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX

Nov 21, 2023, 8:06 AM EST - 1 year ago

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

Nov 10, 2023, 9:34 AM EST - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:31 AM EST - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

Sep 29, 2023, 12:30 PM EDT - 1 year ago

ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering

Sep 22, 2023, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI

Sep 21, 2023, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System

Sep 19, 2023, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System

Sep 14, 2023, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

Aug 7, 2023, 10:26 PM EDT - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 4:05 PM EDT - 2 years ago

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update

Jun 29, 2023, 8:31 AM EDT - 2 years ago

ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software

Jun 28, 2023, 8:31 AM EDT - 2 years ago

ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting